EA
NVCR icon

Ellsworth Advisors’s NovoCure NVCR Stock Holding History

Ellsworth Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,131
Closed -$414K – 162
2021
Q1 		$414K Buy
3,131
+389
+14% +$61.5K 0.25% 84
2020
Q4 		$474K Buy
2,742
+401
+17% +$54.9K 0.34% 69
2020
Q3 		$261K Buy
+2,341
New +$187K 0.26% 71

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ellsworth Advisors's NVCR Position: Q2 2021 in Review

Ellsworth Advisors sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 3,131 shares — an estimated $414K sold.

Ellsworth Advisors first reported a position in NVCR in Q3 2020 and held it in 3 quarters. The position peaked at $474K in Q4 2020. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

  • Ellsworth Advisors reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
  • Ellsworth Advisors sold 3,131 NovoCure shares in Q2 2021, an estimated $414K.
  • Ellsworth Advisors first reported a position in NovoCure in Q3 2020 and held it in 3 quarters.
  • Ellsworth Advisors's NovoCure position peaked at $474K in Q4 2020.
  • 361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Ellsworth Advisors's 13F filing for Q2 2021, filed 19 Jul 2021.